Welcome to PrEP Watch, a clearinghouse for information on pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP Watch includes information on data, additional research, cost, access and advocacy efforts in the United States and across the globe.

Resources to Understand PrEP

PrEP is a new and emerging HIV prevention intervention in which HIV-negative individuals take an antiretroviral (ARV) to reduce their individual risk of acquiring HIV. More here.

PrEP Data to-Date

A number of large-scale trials from a range of populations and in different areas of the world have generated data showing that daily oral TDF/FTC (Truvada) is safe and effective to reduce the risk of HIV infection for HIV-negative people. More here.


Guidelines for prescribing and using PrEP are available from a range of groups, including state health departments in the US, the US Centers for Disease Control (CDC) and national-level clinician groups as well as guidelines on international demonstration projects from the World Health Organization. More here.

Implementing PrEP in the “Real World”

Depending on location, communities are at varying stages of implementing PrEP. In the US the Food and Drug Administration (FDA) has approved daily Truvada for HIV prevention, and some communities in the US are exploring how it might best be delivered. Outside of the US, Truvada as PrEP is not approved by local regulators and in most cases remains inaccessible outside of research studies. Country-specific information is being collected. More here.

Cost, Access and Using PrEP

There is a growing body of information on how to access PrEP and how its cost can be covered in the US. There is limited access elsewhere outside of clinical trials or demonstration projects. More here.

Ongoing research

At the same time, additional clinical trial research is ongoing to test new regimens—twice-weekly, for example—and different ARVs, like maraviroc. More here.

Local Advocacy

Advocacy efforts supporting both the PrEP research pipeline and PrEP access for populations most in need are active in areas around the world. More here

Other HIV Prevention Research

PrEP is just one element of the ARV-based and wider biomedical HIV prevention agenda, which include a range of proven approaches and others under study. More here.

Quick Links

What’s new

Prioritisation is Crucial for the Success of PrEP, Model Confirms

A mathematical model developed by two researchers at Imperial College in London, and based on what would happen if pre-exposure prophylaxis (PrEP) was introduced to a high-prevalence region in Kenya, shows that PrEP could be a ‘runaway success’ or a ‘runaway failure’, depending on a number of factors.

New PrEP Assistance Program is the Latest Step in the Effort to End the Epidemic in New York State by the End of 2020

Governor Andrew M. Cuomo announced the launch of a new PrEP Assistance Program in NY. The program will reimburse eligible providers for the package of care and support services required for eligible individuals receiving PrEP.

The Future of Pre-Exposure Prophylaxis

In this video an international panel of experts speak on the future of PrEP. AVAC’s Executive Director, Mitchell Warren, urges us to “begin to act on the evidence” and use PrEP more widely outside clinical trials to see a public health impact.

Success with PrEP: Next steps to support policy decisions in Southern and East Africa

In a meeting convened by AVAC, WHO and UNAIDS, participants shared current experiences and helped define a structured approach to considering the integration of PrEP in HIV prevention programs in the region.

Pre-exposure Prophylaxis Works—It’s Time to Deliver

A commentary from the leadership of the International AIDS Society on the urgency and relevance of implementing daily oral PrEP as an HIV prevention option for all people at risk of HIV. PrEP isn’t a magic bullet or a strategy that will be everything for everyone, but it’s a key choice to have at the right place at the right time for people in need.

#DailyBlue PrEP Campaign

The HRC is raising PrEP awareness. If you are on PrEP and want to share your story, use #DailyBlue on Instagram! More details here.

PrEP News at CROI

New data from PROUD, IPERGAY and Partners PrEP on oral PrEP strategies; from FACTS 001 on tenofovir gel. Get the latest statements and background here.